US45773H4092 - Common Stock
INOVIO PHARMACEUTICALS INC
NASDAQ:INO (4/26/2024, 7:00:02 PM)
After market: 10.38 -0.19 (-1.8%)10.57
+0.45 (+4.4%)
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 184 full-time employees. The firm is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. The Company’s lead candidates are focused on diseases associated with HPV. Its DNA medicines pipeline includes INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for the treatment of HPV-related Cervical HSIL, INO-5401 for the treatment of Glioblastoma Multiforme (GBM), INO-5151 (INO-5150 + INO-9012) for the treatment of Prostate Cancer, INO-4800 for COVID-19, INO-4201 for Ebola Virus Disease, INO-4700 for Middle East Respiratory Syndrome (MERS) and INO-4500 for Lassa Fever. Its DNA medicine platform consists of DNA plasmids and its investigational smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of three models.
INOVIO PHARMACEUTICALS INC
6769 Mesa Ridge Rd.
San Diego CALIFORNIA 19462
P: 18584103134
CEO: J. Joseph Kim
Employees: 184
Website: https://www.inovio.com/
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INO earnings call for the period ending December 31, 2023.
INO stock results show that Inovio Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the fourth quarte...
Here you can normally see the latest stock twits on INO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: